Combined Immunodeficiency (CID) Cell Models for Research

Combined immunodeficiency (CID) comprises a group of rare inherited disorders characterized by defects in both T and B cell function, leading to severe infections, failure to thrive, and early mortality if untreated. The incidence is estimated at 1 in 50,000 to 1 in 100,000 live births, though precise global data are limited due to underdiagnosis in resource-poor settings. According to the World Health Organization (WHO), primary immunodeficiencies, including CID, are recognized as a global health priority, with efforts to improve diagnosis and access to care. The clinical impact is profound: without hematopoietic stem cell transplantation (HSCT) or gene therapy, many affected infants die within the first year of life from opportunistic infections. Newborn screening for T-cell receptor excision circles (TRECs) has improved early detection in some countries, but global coverage remains uneven. Key risk factors include consanguinity, family history, and specific founder mutations in certain populations. The 5-year survival after HSCT varies by donor type and conditioning regimen, ranging from 60% to over 90% in optimal settings, according to data from the National Cancer Institute (NCI) and the Primary Immune Deficiency Treatment Consortium (PIDTC).

CID is an ideal model for mechanistic studies of immune development and function because it is monogenic in many cases, with well-defined genetic causes. Subtypes include X-linked severe combined immunodeficiency (SCID) due to IL2RG mutations, autosomal recessive SCID caused by defects in JAK3, RAG1/2, ADA, and others. These disorders offer clear genotype-phenotype correlations and are amenable to gene editing. Public datasets such as ClinVar, NCBI Gene, and the Human Gene Mutation Database (HGMD) provide extensive mutation information. Open questions include the mechanisms of immune reconstitution after gene therapy, the role of hypomorphic mutations in atypical CID, and the development of targeted therapies for less severe forms. The rarity of CID necessitates collaborative research and the use of engineered cell models to study rare variants and test novel therapeutics.

CID is not a malignant disease, but the molecular pathways disrupted are critical for immune cell development and function. The major pathways include:

1. Cytokine signaling: Mutations in IL2RG, JAK3, or IL7R impair interleukin signaling, leading to defective T and NK cell development.

2. V(D)J recombination: Defects in RAG1, RAG2, or Artemis (DCLRE1C) block T and B cell receptor assembly, causing radiosensitive SCID.

3. Purine metabolism: Adenosine deaminase (ADA) deficiency leads to accumulation of toxic metabolites that kill lymphocytes.

4. Thymic selection: Mutations in FOXN1 or CD3 subunits disrupt thymic epithelial cell function and T cell maturation.

These pathways are essential for lymphocyte survival, proliferation, and differentiation, and their disruption results in the combined immunodeficiency phenotype.

The following table summarizes the most common genetic alterations in CID, based on data from ClinVar, NCBI Gene, and the literature. Frequencies are approximate and vary by population.

Note: Frequencies are based on cohort studies and may not reflect global distribution. Data from ClinVar and NCBI Gene.

The signaling networks disrupted in CID include:

• • JAK-STAT pathway: Mutations in JAK3 or IL2RG prevent STAT5 phosphorylation, blocking T and NK cell development.
• • V(D)J recombination pathway: RAG1/2 and Artemis defects impair DNA repair and recombination, leading to lack of mature T and B cells.
• • Purine salvage pathway: ADA deficiency causes accumulation of dATP and adenosine, which are toxic to lymphocytes.
• • T cell receptor signaling: CD3 subunit mutations impair TCR assembly and signal transduction.
• • Thymic development: FOXN1 mutations disrupt thymic epithelium, affecting T cell maturation.

These networks are interconnected, and their perturbation results in the combined immunodeficiency phenotype.

Several cell lines are used to study CID, including patient-derived lymphoblastoid cell lines (LCLs) and immortalized T cell lines. However, these often have limited proliferative capacity and may not fully recapitulate the disease. The table below lists commonly used cell lines and their key mutations.

Organoids derived from patient tissues or induced pluripotent stem cells (iPSCs) offer advantages such as 3D structure, multicellular interactions, and patient-specific genetics. Thymic organoids and lymphoid organoids are emerging as powerful tools for studying CID and testing gene therapy approaches.

Animal models are crucial for understanding CID pathogenesis and testing therapies. Examples include:

• • Il2rg knockout mice: Recapitulate X-linked SCID, lack T and NK cells.
• • Jak3 knockout mice: Show defective T and B cell development.
• • Rag1/2 knockout mice: Lack mature T and B cells, widely used for engraftment studies.
• • Ada knockout mice: Develop severe immunodeficiency and metabolic toxicity.
• • Canine models: X-linked SCID in dogs has been used for gene therapy trials.
• • Humanized mice: Engrafted with human hematopoietic stem cells, used to study human immune development.

These models have been instrumental in preclinical development of gene therapy and HSCT.

CRISPR-Cas9 technology enables the creation of isogenic cell lines that carry specific CID-associated mutations, providing controlled systems for mechanistic studies and drug testing. Examples include:

• • IL2RG knockout in Jurkat or HEK293T cells to study cytokine signaling defects.
• • JAK3 knockout in T cell lines to model autosomal recessive SCID.
• • RAG1 knockout in B cell lines to study V(D)J recombination.
• • Knock-in of patient-specific mutations (e.g., IL2RG p.R226H) to investigate hypomorphic phenotypes.
• • Reporter lines with fluorescent tags on immune markers for high-throughput screening.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are generated using CRISPR and other gene editing technologies, and are quality-controlled for genomic integrity and functional outcomes. They enable researchers to study disease mechanisms, validate drug targets, and screen for therapeutic compounds without the need for patient samples.

Gene-edited cell models allow systematic interrogation of gene function in immune cells. For example, knockout of IL2RG in a T cell line can confirm its essential role in cytokine signaling, while knock-in of specific mutations can reveal genotype-phenotype relationships. CRISPR screens in these cells can identify modifiers of disease severity or synthetic lethal interactions. Such studies provide insights into basic immunology and may uncover new therapeutic targets.

Isogenic pairs of cell lines (wild-type vs. mutant) are powerful tools for drug screening. For instance, a JAK3 knockout line can be used to test JAK inhibitors or other compounds that bypass the defect. Resistance modeling can be performed by introducing secondary mutations and screening for drugs that overcome resistance. These approaches accelerate preclinical drug development for CID and related immunodeficiencies.

CRISPR synthetic lethality screens in gene-edited cells can identify biomarkers that predict response to specific therapies. For example, cells with RAG1 mutations may be sensitive to DNA repair inhibitors, revealing potential therapeutic vulnerabilities. Such screens can also uncover biomarkers for disease progression or treatment response, guiding personalized medicine approaches.

The following databases provide valuable information for CID research:

These resources support target discovery, mutation analysis, and functional interpretation.